Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [21] Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia
    Tesic, Danka
    Kostic, Marina
    Paunovic, Dusko
    Jankovic, Slobodan M.
    KARDIOLOGIA POLSKA, 2015, 73 (04) : 287 - 295
  • [22] Perioperative atrial fibrillation
    Haysley, J.
    Soliman-Aboumarie, H.
    Huang, J.
    Kalra, D. K.
    BJA EDUCATION, 2025, 25 (03) : 99 - 106
  • [23] Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting
    Kovacs, Boldizsar
    Yakupoglu, Haci Yakup
    Eriksson, Urs
    Krasniqi, Nazmi
    Duru, Firat
    CARDIOLOGY JOURNAL, 2023, 30 (01) : 82 - 90
  • [24] Is Catheter Ablation a Mature Fruit for Treatment of Atrial Fibrillation? - Is Catheter Ablation Established as a Treatment Option of Atrial Fibrillation? (Con)
    Yamashita, Takeshi
    CIRCULATION JOURNAL, 2010, 74 (09) : 1978 - 1982
  • [25] Atrial fibrillation: Adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction
    Boriani, Giuseppe
    Biffi, Mauro
    Diemberger, Igor
    Domenichini, Giulia
    Marziali, Alessandro
    Martignani, Cristian
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 140 (02) : 242 - 243
  • [26] Atrial Fibrillation and Atrial Flutter: Medical Management
    Chen, Jane
    CLINICS IN GERIATRIC MEDICINE, 2012, 28 (04) : 635 - +
  • [27] Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter
    Jastrzebski, Marek
    KARDIOLOGIA POLSKA, 2008, 66 (11) : 1221 - 1224
  • [28] Comparative effectiveness and safety of antazoline-based and propafenone-based strategies for pharmacological cardioversion of short-duration atrial fibrillation in the emergency department
    Farkowski, Michal M.
    Maciag, Aleksander
    Zurawska, Malgorzata
    Pytkowski, Mariusz
    Kowalik, Ilona
    Wozniak, Jacek
    Sterlinski, Maciej
    Szwed, Hanna
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (06): : 381 - 387
  • [29] Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation
    Jin, Shuyu
    Chen, Haowei
    Fang, Xianhong
    Liao, Hongtao
    Zhan, Xianzhang
    Fu, Lu
    Jiang, Junrong
    Ye, Xingdong
    Liu, Huiyi
    Chen, Yanlin
    Pu, Sijia
    Wu, Shulin
    Deng, Hai
    Lin, Weidong
    Xue, Yumei
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2024, 47 (12): : 1642 - 1649
  • [30] Reappraising the role of class Ic antiarrhythmics in atrial fibrillation
    Tsiachris, Dimitris
    Doundoulakis, Ioannis
    Tsioufis, Panagiotis
    Pagkalidou, Eirini
    Antoniou, Christos-Konstantinos
    Zafeiropoulos, Stefanos M.
    Gatzoulis, Konstantinos A.
    Tsioufis, Konstantinos
    Stefanadis, Christodoulos
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (06) : 1039 - 1045